10 October 2018 in Expert Review of Gastroenterology & Hepatology
Introduction: Crohn’s disease and Ulcerative Colitis are forms of inflammatory bowel disease (IBD), chronic diseases treated with medical and surgical therapy. Patients with IBD are treated with potent immunomodulatory agents, leading to immunosuppression, and the potential for opportunistic infections. In 2014, the ECCO guidelines were released to guide the prevention, diagnosis and treatment of a variety of these opportunistic infections. Since 2014, there have been a number of new agents released as well as a significant expansion in our knowledge of the safety profile of IBD medications. In this paper we review the literature after 2014 regarding opportunistic infections and updates on safety data. Areas covered: We review updates in immunomodulatory therapies for IBD and opportunistic infections since the 2014 ECCO guidelines were published. Expert commentary: The prevention, diagnosis and treatment of opportunistic infections continues to evolve, as new drugs are approved, and the use of a combination of biologic agents are considered for therapy in clinical trials. What causes some patients to fail to respond to vaccination, or for others to develop severe infections, remains unclear. Improved risk stratification for opportunistic infections in IBD patients and updated ECCO 2014 guidelines would be of significant benefit.
19 November 2010 in Blood
Abstract 1018 Th17 cells are thought to be meta-stable, short-lived end-effector T lymphocytes and purportedly have a limited ability to form memory. Paradoxically, we have recently reported that tumor-specific Th17-polarized CD4+ T cells eradicate established tumor more efficiently than their Th1 counterparts did. Mounting evidence suggests that the advanced differentiation stage of the effectors impairs their self-renewal ability and negatively correlates with the anti-tumor functionality of T cells upon adoptive transfer. We hypothesized that in vivo advantage of Th17-polarized cells over Th1 cells might result from more naïve, less senescent properties preserved during the initial in vitro programming. Using a TCR gene engineered Th17 cells we showed that IL-17A or CCR6 signaling contributed only modestly to tumor rejection, and that Th17-polarized cells had to activate type 1 defining transcription factor tbx21 (t-bet) and secrete IFN-γ in vivo, underscoring the less mature, dualistic nature of type 17 responses. Although we confirmed that Th17-polarized cells acquired an end-effector-like phenotype (CD27low/CD62Llow), we found that they also exhibited lower levels of inhibitory receptors and multiple markers of T cell terminal differentiation. While previous work used IL-17 to trace the fate of Th17 cells, in a congenic system we observed that most type 17 cells lost the capacity to produce IL-17A during in vivo expansion, although they efficiently persisted and formed memory. Serial global gene expression profiling demonstrated the loss of IL-17A expression and the acquisition of a phenotype with Th1-like features, nevertheless the molecular signature of Th17-derived cells remained significantly distinct from that of Th1-derived memory cells. Using gene set enrichment analysis (GSEA) we observed a highly significant non-random distribution of genes associated with less mature memory T cell subset in Th17-derived population. Ex vivo recovered Th17-derived memory cells expressed high levels of genes related to improved survival, functionality and self-renewal, including wnt/β-catenin target tcf-7, thus closely resembling the pattern previously described by us in a self-renewing memory stem-like CD8+ subset generated pharmacologically. We confirmed the activity of this stem-related pathway during the initial Th17 polarization, as evidenced by the striking accumulation of β-catenin and progressive induction of tcf-7 to a level above one found in naïve cells. In summary, we report that Th17-derived cells expressed more “stem-like” characteristics distinct from Th1-derived effectors as evidenced by their molecular signature and dramatically enhanced ability to survive in vivo and reject tumor. This suggests that Th17-polarizing conditions trigger a distinctive developmental program that dissociates proliferation from maturation.